Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that the U.
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced the initiation of active patient recruitment in ENCORE-NF, a randomized, double-blind, placebo-controlled, Phase 2b clinical trial evaluating emricasan, the …
Analysts weigh in on biotechnology company Conatus Pharmaceuticals Inc (NASDAQ:CNAT) and vision chip company Mobileye NV (NYSE:MBLY), as news of positive Phase II study of liver cirrhosis and strategic …
Netflix, Inc. (NASDAQ:NFLX) is down 2.
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced the presentation of two posters, both addressing preclinical results with the company’s pan-caspase inhibitors, at The Liver Meeting®, the …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced that a late-breaking abstract detailing results from the company’s multicenter Phase 2 Portal Hypertension clinical trial in patients with …
Analysts are weighing in on two biotechnology companies Keryx Pharmaceutical (NASDAQ:KERX) and Conatus Pharmaceuticals Inc (NASDAQ:CNAT), with mixed ratings. Keryx Pharmaceutical BTIG analyst Hartaj Singh came out with a …
Roth Capital’s healthcare analyst Elemer Piros weighed in today with his views on Conatus Pharmaceuticals Inc (NASDAQ:CNAT), after the company announced positive data on the early …
Keryx Biopharmaceuticals (NASDAQ:KERX) rose more than 12% in pre-market trading up to $4.40 after this morning’s announcement that the company received approval in Europe …
